SP-8203

DRUG3 trials

Sponsors

Shin Poong Pharmaceutical Co. Ltd.

Conditions

Ischemic Stroke

Phase 1

Safety, Tolerability and Pharmacokinetics of SP-8203

CompletedNCT01757795

Shin Poong Pharmaceutical Co. Ltd.Ischemic Stroke

Start: 2013-12-23End: 2015-03-11Updated: 2020-07-22

Phase 2

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

CompletedNCT04479449

Shin Poong Pharmaceutical Co. Ltd.Ischemic Stroke

Start: 2019-03-18End: 2020-12-18Updated: 2023-03-08

Phase 3

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

RecruitingNCT06660719

Shin Poong Pharmaceutical Co. Ltd.Ischemic Stroke

Start: 2025-02-14End: 2027-03-30Target: 852Updated: 2025-03-07